Inhibitors of leukotriene A4 hydrolase

A compound having the Formula (I):

• wherein:
• R is the group;
• r is 0;
• q is 1;
• R1a, R1b, R1c, R1d and R1e are each independently hydrogen, OR10, C(O)OR10, C(O)R10, optionally substituted C1-C12 alkyl, optionally substituted C2-C12 alkenyl, optionally substituted C2-C12 alkynyl, optionally substituted C3-C15 cycloalkyl, optionally substituted C3-C15 cycloalkenyl, halo, cyano, optionally substituted aryl, optionally substituted 3- to 18-membered heteroaryl, or optionally substituted 3- to 18-membered heterocyclyl;
• R3 is —O—;
• R4 is a direct bond;
• each R5a and R6a are each independently hydrogen and optionally substituted C1-C6 alkyl;
• R7 is —C(R5b)2—R15;
• each R5b is independently selected from the group consisting of hydrogen and optionally substituted C1-C6 alkyl:
• R15 is selected from the group consisting of C(O)R10, C(O)OR10, C(O)—R13—N(R10)R11, optionally substituted aryl, and optionally substituted 3- to 18-membered heteroaryl;
• each R9 is independently —OR10, optionally substituted C1-C12 alkyl, optionally substituted C2-C12 alkenyl, optionally substituted C2-C12 alkynyl, halo, optionally substituted aryl, or optionally substituted heteroaryl;
• each R10 and R11 is independently selected from the group consisting of hydrogen, optionally substituted C1-C12 alkyl, optionally substituted C2-C12 alkenyl, optionally substituted C2-C12 alkynyl, optionally substituted C3-C15 cycloalkyl, optionally substituted C3-C15 cycloalkenyl, optionally substituted aryl, optionally substituted 3- to 18-membered heteroaryl, and optionally substituted 3- to 18-membered heterocyclyl;
• each R13 is independently a direct bond, an optionally substituted straight or branched C1 to C12 alkylene chain, an optionally substituted straight or branched C2 to C12 alkenylene chain, or an optionally substituted straight or branched C3 to C12 alkynylene chain;
• and
• R14 is an optionally substituted pyrrolidinyl;
• wherein each of the optionally substituted moieties is independently optionally substituted by one, two or three substituents independently selected from the group consisting of —C1-C12 alkyl, —C2-C12 alkenyl, —C2-C12 alkynyl, —C3-C15 cycloalkyl, —C3-C15 cycloalkenyl, C3-C15 cycloalkynyl, -3 to 18-membered heterocyclic, —F, —Cl, —Br, —I, —OH, —NO2, —N3, —CN, —NH2, oxo, thioxo, —NHRx, —NRxRx, dialkylamino, -diarylamino, -diheteroarylamino, —ORx, —C(O)ORy, —C(O)Ry, —C(O)C(O)Ry, —OCO2Ry, —OC(O)Ry, OC(O)C(O)Ry, —NHC(O)Ry, —NHCO2Ry, —NHC(O)C(O)Ry, —NHC(S)NH2, —NHC(S)NHRx, —NHC(NH)NH2, —NHC(NH)NHRx, —NHC(NH)Rx, —C(NH)NHRx, —NRxC(O)Rx, —NRxCO2Ry, —NRxC(O)C(O)Ry, —NRxC(S)NH2, —NRxC(O)NRxRx, —NRxS(O)2NRxRx, —NRxC(S)NHRx, —NRxC(NH)NH2, —NRxC(NH)NHRx, —NRxC(NH)Rx, —C(NRx)NHRx—S(O)nRy, —NHSO2Rx, —CH2NH2, —CH2SO2CH3, —(C═NRx)Rx;
• -aryl, -arylalkyl, -3 to 18-membered heteroaryl, -3 to 18-membered heteroarylalkyl, polyalkoxyalkyl, -polyalkoxy, -methoxymethoxy, -methoxyethoxy, —SH, —S—Rx, and -methylthiomethyl,
• Rx is selected from the group consisting of hydrogen, —C1-C12 alkyl, —C2-C12 alkenyl, C2-C12 alkynyl, —C3-C15 cycloalkyl, -aryl, -3 to 18-membered heteroaryl, and -3 to 18-membered heterocyclic;
• —Ry is selected from the group consisting of hydrogen, —C1-C12 alkyl, —C2-C12 alkenyl, —C2-C12 alkynyl, —C3-C15 cycloalkyl, -aryl, -3 to 18-membered heteroaryl, -3 to 18-membered heterocyclic, —NH2, —NH—C1-C12 alkyl, —NH—C2-C12 alkenyl, —NH—C2-C12-alkynyl, —NH—C3-C15 cycloalkyl, —NH-aryl, —NH-3 to 18-membered heteroaryl, and —NH-3 to 18-membered heterocyclic, and
• n is 0, 1 or 2:
• as a single stereoisomer or as a mixture of stereoisomers;
• or a pharmaceutically acceptable salt thereof.